Fri.Dec 13, 2024

article thumbnail

Japanese researchers test pioneering drug to regrow teeth

Medical Xpress

People with missing teeth may be able to grow new ones, say Japanese dentists testing a pioneering drug they hope will offer an alternative to dentures and implants.

Drugs 113
article thumbnail

AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy

Pharmaceutical Technology

AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.

246
246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI-powered blood test can spot earliest sign of breast cancer

Medical Xpress

A new screening method that combines laser analysis with a type of AI is the first of its kind to identify patients in the earliest stage of breast cancer, a study suggests.

126
126
article thumbnail

FDA accepts Sobi North America’s thrombocytopenia therapy sNDA

Pharmaceutical Technology

The US FDA has accepted Sobi North Americas avatrombopag (DOPTELET) sNDA to treat paediatric immune thrombocytopenia.

147
147
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

After Moderna's pediatric RSV vaccine trial hold, expert panel says more testing is needed

Fierce Pharma

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that involve young children, experts from an FDA advisory panel expressed their | An FDA advisory committeeexamining the halt of a trial of two Moderna respiratory syncytial virus (RSV) vaccines because of severe lower respiratory tract infections (LRTIs)echoed frustration in knowledge gaps about the disease and said that more testing is needed.

article thumbnail

Conduit and Sarborg link to optimise AI drug development

Pharmaceutical Technology

Conduit has signed an agreement with Sarborg to leverage advanced artificial intelligence and cybernetics.

More Trending

article thumbnail

A novel, toothy approach to innovating randomization in clinical trials

Pharmaceutical Technology

New eClinical platforms from Merative are helping clinical trials develop effective randomization strategies.

article thumbnail

Light-induced gene therapy disables cancer cells' mitochondria

Medical Xpress

Researchers are shining a light on cancer cells' energy centersliterallyto damage these power sources and trigger widespread cancer cell death. In a new study, scientists combined strategies to deliver energy-disrupting gene therapy using nanoparticles manufactured to zero in only on cancer cells. Experiments showed the targeted therapy is effective at shrinking glioblastoma brain tumors and aggressive breast cancer tumors in mice.

article thumbnail

Obesity Drug Petrelintide Advances into Phase IIb

XTalks

Zealand Pharma has commenced its global Phase IIb ZUPREME-1 trial, enrolling the first participant to evaluate petrelintide, a long-acting amylin analog, as a potential investigational treatment for people with overweight or obesity. The study will assess the drugs effects on body weight, safety and tolerability over a 42-week period. Petrelintide, administered once a week under the skin, targets obesity through its action as an amylin analog, a hormone co-secreted with insulin from the pancreas

Drugs 102
article thumbnail

An unexpected side effect: Intermittent fasting may slow hair regrowth

Medical Xpress

Intermittent fasting has proven benefits for metabolic health, but a new study shows that it could slow hair growthat least in mice. Researchers report December 13 in the journal Cell that mice subjected to intermittent fasting regimes showed improved metabolic health but slower hair regeneration compared to mice with 24/7 access to food.

Research 104
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Risk adjusted net present value: What is the current valuation of Avidity Biosciences’s AOC-1020?

Pharmaceutical Technology

AOC-1020 is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Facioscapulohumeral Muscular Dystrophy (FSHD).

100
100
article thumbnail

From Yemen to France, research reveals spread of highly drug-resistant cholera strain

Medical Xpress

Scientists from the National Reference Center for Vibrios and Cholera at the Institut Pasteur, in collaboration with the Center hospitalier de Mayotte, have revealed the spread of a highly drug-resistant cholera strain. The study was published on December 11, 2024 in the New England Journal of Medicine.

Drugs 103
article thumbnail

Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics’s CLN-619?

Pharmaceutical Technology

CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Ovarian Cancer;Cervical Cancer;Endometrial Cancer.

Antibody 100
article thumbnail

Blenrep Combination Extends Survival in Relapsed Multiple Myeloma

XTalks

The DREAMM-7 Phase III trial has spotlighted the potential of Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) to improve survival outcomes for relapsed or refractory multiple myeloma. Blenrep was previously withdrawn from the US market in 2022 after the DREAMM-3 trial failed to confirm its initial accelerated approval.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Risk adjusted net present value: What is the current valuation of IN8bio’s INB-400?

Pharmaceutical Technology

INB-400 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM).

Gene 100
article thumbnail

Who Will Pay for Prescription Drugs in 2032: Four Takeaways from the New Government Forecasts (rerun)

Drug Channels

This week, Im rerunning some popular posts while I prepare for todays Drug Channels Outlook 2025 live video webinar. (If you sign up before 12 p.m. ET, you can attend the live event.) Click here to see the original post. The econowonks at the Centers for Medicare & Medicaid Services (CMS) recently released the latest projections for U.S. spending on healthcare.

article thumbnail

Risk adjusted net present value: What is the current valuation of Vigil Neuroscience’s Iluzanebart?

Pharmaceutical Technology

Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.

Antibody 100
article thumbnail

Gut-immune connection could boost immunotherapy effectiveness in recurrent ovarian cancer

Medical Xpress

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the "tumor-immune-gut axis," and its role in influencing immunotherapy responses in patients with recurrent ovarian cancer.

97
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Risk adjusted net present value: What is the current valuation of Jazz Pharmaceuticals’s JZP-898?

Pharmaceutical Technology

JZP-898 is a fusion protein commercialized by Jazz Pharmaceuticals, with a leading Phase I program in Metastatic Renal Cell Carcinoma;Metastatic Transitional (Urothelial) Tract Cancer.

Protein 100
article thumbnail

Some aging cells heal wounds, others cause harm: Study shows how to distinguish between the two

Medical Xpress

Lengthening life by eliminating old, inflammatory cells is a tantalizing idea, but anti-aging researchers suspect it's oversimplified. Now, University of Connecticut researchers confirm in an article published in the Nov. 13 issue of Nature Aging that aged, inflammatory cells are diverse, and some play important roles in the body.

article thumbnail

Risk adjusted net present value: What is the current valuation of Aquestive Therapeutics’s Epinephrine?

Pharmaceutical Technology

Epinephrine is a small molecule commercialized by Aquestive Therapeutics, with a leading Phase III program in Anaphylaxis.

100
100
article thumbnail

Pioneering MRI method spots pre-malignant pancreatic lesions for the first time

Medical Xpress

Precursor lesions of pancreatic cancer are very difficult to characterize with magnetic resonance imaging (MRI). But now, in a new study, researchers led by Noam Shemesh and Carlos Bilreirorespectively, head of the Preclinical MRI lab at Champalimaud Research and a doctor at the Champalimaud Clinical Center's Radiology Departmenthave shown, for the first time, that a particular form of MRI, called Diffusion Tensor Imaging (DTI), is capable of robustly detecting pre-malignant lesions in the pancr

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Risk adjusted net present value: What is the current valuation of Solid Biosciences’s SGT-003?

Pharmaceutical Technology

SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Phase II program in Duchenne Muscular Dystrophy.

article thumbnail

Photocurrent-responsive coating cuts bone-to-implant integration time in half

Medical Xpress

A research team has developed an innovative photocurrent-responsive implant surface to accelerate bone-to-implant integration after orthopedic surgery. The cutting-edge coating has been shown to shorten the integration time to just two weeks, doubling the speed and expediting post-operative recovery, as well as reducing the risk of rejection.

article thumbnail

Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics’s TN-401?

Pharmaceutical Technology

TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy.

article thumbnail

AI tool analyzes placentas at birth for faster detection of neonatal and maternal problems

Medical Xpress

A newly developed tool that harnesses computer vision and artificial intelligence (AI) may help clinicians rapidly evaluate placentas at birth, potentially improving neonatal and maternal care, according to new research from scientists at Northwestern Medicine and Penn State.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Risk adjusted net present value: What is the current valuation of Forte Biosciences’s FB-102?

Pharmaceutical Technology

FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease.

Antibody 100
article thumbnail

A low omega-6, omega-3 rich diet and fish oil may slow prostate cancer growth

Medical Xpress

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators offers new evidence that dietary changes may help reduce cancer cell growth in patients undergoing active surveillance, a treatment approach that involves regular monitoring of the cancer without immediate intervention.

92
article thumbnail

Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics’s CTX-131?

Pharmaceutical Technology

CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Cervical Cancer;Endometrial Cancer.

Gene 100
article thumbnail

Key genetic mechanism provides insights into facial development and congenital issues

Medical Xpress

An international team of researchers has identified a key genetic mechanism that regulates the formation and migration of cranial neural crest cells, which are essential for developing facial structures.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud